341 related articles for article (PubMed ID: 29802472)
1. Biomarker Discovery in Cardio-Oncology.
Vohra A; Asnani A
Curr Cardiol Rep; 2018 May; 20(7):52. PubMed ID: 29802472
[TBL] [Abstract][Full Text] [Related]
2. Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues.
Bracun V; Aboumsallem JP; van der Meer P; de Boer RA
Curr Oncol Rep; 2020 Jun; 22(7):67. PubMed ID: 32514994
[TBL] [Abstract][Full Text] [Related]
3. The Role of Biomarkers in Cardio-Oncology.
Ananthan K; Lyon AR
J Cardiovasc Transl Res; 2020 Jun; 13(3):431-450. PubMed ID: 32642841
[TBL] [Abstract][Full Text] [Related]
4. Precision Cardio-oncology: Update on Omics-Based Diagnostic Methods.
Kuang Z; Kong M; Yan N; Ma X; Wu M; Li J
Curr Treat Options Oncol; 2024 May; 25(5):679-701. PubMed ID: 38676836
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond.
Attanasio U; Di Sarro E; Tricarico L; Di Lisi D; Armentaro G; Miceli S; Fioretti F; Deidda M; Correale M; Novo G; Sciacqua A; Nodari S; Cadeddu C; Tocchetti CG; Palazzuoli A; Mercurio V
Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397436
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers as Predictors of Cardiac Toxicity From Targeted Cancer Therapies.
Witteles RM
J Card Fail; 2016 Jun; 22(6):459-64. PubMed ID: 27038641
[TBL] [Abstract][Full Text] [Related]
7. Cancer Therapy-Related Cardiac Dysfunction: Unresolved Issues.
Marwick TH
Can J Cardiol; 2016 Jul; 32(7):842-6. PubMed ID: 27343742
[TBL] [Abstract][Full Text] [Related]
8. Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.
Gulati G; Heck SL; Røsjø H; Ree AH; Hoffmann P; Hagve TA; Norseth J; Gravdehaug B; Steine K; Geisler J; Omland T
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29118031
[TBL] [Abstract][Full Text] [Related]
9. Role of biomarkers in monitoring antiblastic cardiotoxicity.
Novo G; Cadeddu C; Sucato V; Pagliaro P; Romano S; Tocchetti CG; Zito C; Longobardo L; Nodari S; Penco M
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e27-e34. PubMed ID: 27755240
[TBL] [Abstract][Full Text] [Related]
10. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
Pudil R; Mueller C; Čelutkienė J; Henriksen PA; Lenihan D; Dent S; Barac A; Stanway S; Moslehi J; Suter TM; Ky B; Štěrba M; Cardinale D; Cohen-Solal A; Tocchetti CG; Farmakis D; Bergler-Klein J; Anker MS; Von Haehling S; Belenkov Y; Iakobishvili Z; Maack C; Ciardiello F; Ruschitzka F; Coats AJS; Seferovic P; Lainscak M; Piepoli MF; Chioncel O; Bax J; Hulot JS; Skouri H; Hägler-Laube ES; Asteggiano R; Fernandez TL; de Boer RA; Lyon AR
Eur J Heart Fail; 2020 Nov; 22(11):1966-1983. PubMed ID: 33006257
[TBL] [Abstract][Full Text] [Related]
11. Role of Cardiovascular Biomarkers in the Risk Stratification, Monitoring, and Management of Patients with Cancer.
Hoeger CW; Hayek SS
Cardiol Clin; 2019 Nov; 37(4):505-523. PubMed ID: 31587791
[TBL] [Abstract][Full Text] [Related]
12. Circulating Biomarkers for Cardiotoxicity Risk Prediction.
Gong FF; Cascino GJ; Murtagh G; Akhter N
Curr Treat Options Oncol; 2021 Apr; 22(6):46. PubMed ID: 33866434
[TBL] [Abstract][Full Text] [Related]
13. New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide.
van Boxtel W; Bulten BF; Mavinkurve-Groothuis AM; Bellersen L; Mandigers CM; Joosten LA; Kapusta L; de Geus-Oei LF; van Laarhoven HW
Biomarkers; 2015 Mar; 20(2):143-8. PubMed ID: 25980453
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in Serum Biomarkers for Risk Stratification and Patient Management in Cardio-Oncology.
Joolharzadeh P; Rodriguez M; Zaghlol R; Pedersen LN; Jimenez J; Bergom C; Mitchell JD
Curr Cardiol Rep; 2023 Mar; 25(3):133-146. PubMed ID: 36790618
[TBL] [Abstract][Full Text] [Related]
15. Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment.
Lenneman CG; Sawyer DB
Circ Res; 2016 Mar; 118(6):1008-20. PubMed ID: 26987914
[TBL] [Abstract][Full Text] [Related]
16. [Biomarkers in cardio-oncology patients].
Totzeck M; Glas M; Rassaf T
Internist (Berl); 2020 Nov; 61(11):1114-1119. PubMed ID: 33025124
[TBL] [Abstract][Full Text] [Related]
17. Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy.
Singh D; Thakur A; Tang WH
Curr Heart Fail Rep; 2015 Jun; 12(3):255-62. PubMed ID: 25869733
[TBL] [Abstract][Full Text] [Related]
18. The role of cardiac biomarkers in cardio-oncology.
Riddell E; Lenihan D
Curr Probl Cancer; 2018 Jul; 42(4):375-385. PubMed ID: 30126650
[TBL] [Abstract][Full Text] [Related]
19. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.
Virani SA; Dent S; Brezden-Masley C; Clarke B; Davis MK; Jassal DS; Johnson C; Lemieux J; Paterson I; Sebag IA; Simmons C; Sulpher J; Thain K; Thavendiranathan P; Wentzell JR; Wurtele N; Côté MA; Fine NM; Haddad H; Hayley BD; Hopkins S; Joy AA; Rayson D; Stadnick E; Straatman L
Can J Cardiol; 2016 Jul; 32(7):831-41. PubMed ID: 27343741
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Research Tools for the Study of Cardiovascular Effects of Cancer Therapy.
Feroze RA; Leya J; Herron T; Hayek SS
J Cardiovasc Transl Res; 2020 Jun; 13(3):417-430. PubMed ID: 32472498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
